"Myasthenia Gravis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)
| Descriptor ID |
D009157
|
| MeSH Number(s) |
C10.114.656 C10.668.758.725 C20.111.258.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Myasthenia Gravis".
Below are MeSH descriptors whose meaning is more specific than "Myasthenia Gravis".
This graph shows the total number of publications written about "Myasthenia Gravis" by people in this website by year, and whether "Myasthenia Gravis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myasthenia Gravis" by people in Profiles.
-
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. J Clin Neurosci. 2024 Jan; 119:76-84.
-
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020 05 01; 77(5):582-592.
-
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173.
-
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 2016 Jan; 13(1):118-31.
-
Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. JAMA Neurol. 2013 Oct; 70(10):1311-4.
-
Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci. 2012 Dec; 1274:68-76.
-
Introduction for myasthenia gravis and related disorders. Ann N Y Acad Sci. 2012 Dec; 1274:vii-viii.
-
Introduction for Myasthenia Gravis and Related Disorders. Ann N Y Acad Sci. 2012 Dec; 1275:vii-viii.
-
Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol. 2012 Dec; 145(3):209-23.
-
Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012 Sep; 46(3):449-53.